Nurix therapeutics reports second quarter fiscal 2021 financial results and provides a corporate update

Initiated phase 1 trial of lead program nx-2127 in patients with relapsed or refractory b-cell malignancies
NRIX Ratings Summary
NRIX Quant Ranking